Project Grant R21CA293766

Award Date 6/15/24
Completion Date 5/31/26
Dollars Obligated $423K
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $1,419,108 will support research to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The research, led by Emory University, will use surgical tissue specimens from a clinical trial to gain insights into how blocking the SEMA4D signaling pathway in combination with immune checkpoint...
The National Cancer Institute (NCI) awarded a $509,448 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University (Stanford University) to support research aimed at overcoming tumor immune tolerance and metastatic progression. The 3-year project, starting August 2024, will identify the specific antigen-presenting cell (APC) populations responsible for inducing tumor-specific regulatory T cells (Tregs) that enable metastasis, and develop...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh aims to investigate how immune checkpoint inhibitor-associated bacteria can modulate tumor immunity and improve the efficacy of immune checkpoint inhibitor (ICI) therapies in treating melanoma. The $636,222 grant, awarded on April 1, 2025, with a completion date of March 31, 2030, will support research to: 1) test whether ICI-associated bacteria can...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $563,233 to The Medical University of South Carolina to investigate strategies for overcoming immunosuppression and improving adoptive T cell therapy for cancer treatment. The key focus is on understanding how the sphingosine kinase 2 (SPHK2) and sphingosine-1-phosphate (S1P) axis regulates the suppressive function of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment....
The National Cancer Institute (NCI) awarded a 3-year, $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The goal of the project is to elucidate the mechanisms by which tumor hypoxia (low oxygen) contributes to immune privilege and treatment resistance in non-small cell lung cancer (NSCLC) tumors. The researchers will investigate the use of mitochondrial inhibitors, such as papaverine (PPV) and SMV-32, to reoxygenate the NSCLC tumor...
This Project Grant award of $1,824,208, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports research focused on understanding the molecular mechanisms driving melanoma progression and tumor immune evasion. The Wistar Institute of Anatomy and Biology, the primary awardee, will lead this 5-year study to investigate how the transcription factor TFEB regulates melanoma cell plasticity and impacts the tumor microenvironment. A sub-award to the University of...
This $167,000 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research at Cedars-Sinai Medical Center to develop a novel combinatorial immunotherapeutic strategy for treating metastatic uveal melanoma. The research aims to first use a tumor debulking approach with the drug combination of trametinib and panobinostat to reduce tumor load, and then apply B7-H3 chimeric antigen receptor (CAR) T-cell therapy to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $312,892.00 to Duke University to study the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The research aims to better understand how ILC3s, which can create immunosuppressive environments, impact the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced melanoma patients. By defining the function of ILC3s in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $577,293 to the Regents of the University of Michigan to develop and test multivalent small circular mRNA (circRNA) vaccines for melanoma combination immunotherapy. The key products and services include: Developing highly stable, modification-free multivalent small circRNA vaccines to elicit potent and durable anti-tumor immunity for immune checkpoint blockade combination therapy in...

UNRAVELING VASCULAR MEDIATED IMMUNE EXCLUSION IN MELANOMA - TITLE: UNRAVELING VASCULAR MEDIATED IMMUNE EXCLUSION IN MELANOMA PROJECT SUMMARY MELANOMA REMAINS THE PRIMARY CAUSE OF SKIN CANCER-RELATED DEATHS. A SIGNIFICANT NUMBER OF PATIENTS SHOW RESISTANCE TO CHECKPOINT INHIBITORS, WHILE OTHERS EXPERIENCE DISEASE PROGRESSION AFTER INITIAL TREATMENT BENEFITS. A DEEPER UNDERSTANDING OF THE MECHANISMS UNDERLYING TUMOR IMMUNE SUPPRESSION IS ESSENTIAL. EFFECTIVE IMMUNOTHERAPY NOT ONLY DEPENDS ON CANCER-SPECIFIC T CELLS BUT ALSO ON THEIR DIRECT CONTACT WITH TUMOR CELLS. THE EXCLUSION OF IMMUNE EFFECTOR CELLS, SUCH AS CYTOTOXIC T CELLS, FROM THE TUMOR PARENCHYMA HAS BEEN LINKED TO REDUCED IMMUNOTHERAPY RESPONSE. HOWEVER, THE EXACT BIOLOGY BEHIND THIS PATTERN IN THE TUMOR MICROENVIRONMENT HAS YET TO BE FULLY UNDERSTOOD. RECENT RESEARCH EMPHASIZES THE POTENTIAL OF TARGETING THE TUMOR VASCULATURE TO IMPROVE TUMOR IMMUNE SUPPRESSION. THE INCREASED VASCULAR LEAKINESS ASSOCIATED WITH VASCULAR DESTABILIZATION HAS BEEN SUGGESTED TO HINDER IMMUNE EFFECTOR CELL INFILTRATION INTO TUMORS. ANGIOPOIETIN- 2 (ANGPT2), A THERAPEUTIC TARGET FOR MANY CANCERS, REGULATES VASCULAR REMODELING BY MODULATING TIE2 RECEPTOR TYROSINE KINASE SIGNALING IN ENDOTHELIAL CELLS. OUR LATEST STUDY DEMONSTRATED THAT ANGPT2 PROMOTES T-CELL EXCLUSION FROM TUMOR CORES BY CAUSING VASCULAR DESTABILIZATION AT THE TUMOR PERIPHERY. THIS HIGHLIGHTS THE NEED FOR A COMPREHENSIVE ANALYSIS OF VASCULAR REGULATION IN TUMOR IMMUNE EXCLUSION AND A DEEPER UNDERSTANDING OF THE MOLECULAR MECHANISM THROUGH WHICH ANGPT2 AFFECTS T-CELL EXCLUSION IN MELANOMA. IN THIS PROPOSED STUDY, WE AIM TO INVESTIGATE THE VASCULAR DETERMINANTS OF IMMUNE EXCLUSION FROM THE TUMOR CORE IN MELANOMA. WE PLAN TO ELUCIDATE THE DEVELOPMENT OF IMMUNE EXCLUSIONS FOR DIFFERENT IMMUNE CELLS DURING MELANOMA PROGRESSION AND EXAMINE THE SPATIAL VASCULAR CHANGES IN CORRELATION WITH IMMUNE CELL POSITIONS (AIM 1). MOREOVER, WE WILL DETERMINE THE MOLECULAR MECHANISMS BEHIND ANGPT2-DRIVEN T-CELL EXCLUSION IN MELANOMA (AIM 2). THIS WILL INVOLVE ELUCIDATING THE RELATIONSHIP BETWEEN ANGPT2 EXPRESSION LEVELS, VASCULAR LEAKINESS, AND T-CELL EXCLUSION IN HUMAN MELANOMA TISSUES AND INVESTIGATING THE EFFECTS OF ANGPT2 INHIBITION ON THE DEVELOPMENT AND PROGRESSION OF T-CELL EXCLUSION USING MOUSE MELANOMA MODELS. EMPLOYING MULTI-OMICS METHODS, WE AIM TO DECIPHER THE MOLECULAR MECHANISMS THROUGH WHICH VASCULAR ABNORMALITIES CONTRIBUTE TO IMMUNE EXCLUSION IN THE TUMOR MICROENVIRONMENT OF MELANOMA. OUR PROPOSED STUDY COULD IDENTIFY NOVEL TARGETS AND BIOMARKERS TO ADDRESS THE IMMUNE EXCLUSION, POTENTIALLY ENHANCING THE EFFECTIVENESS OF EXISTING IMMUNOTHERAPIES.

Posted 6/10/24, 12:00 AM